Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 1/2 2Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 174Myeloid 64Lymphoid 28Thoracic 7Gastrointestinal 5Classical hematology 5Breast 4Plasma cell 3Genitourinary 3Sarcoma 2Head & Neck 2Gynecologic 2Dermatologic 1CNS 1

Conditions

Melanoma 1

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19HhAntag691 19Mycophenolic Acid 18Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Azacitidine × Dermatologic × Clear all
NCT02816021 2026-04-06

Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 2 Completed
24 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡